Highlights of ASH in Asia

The American Society of Hematology
Last Modified: October 7, 2013

Share article


Dates: March 29-30, 2014
Location: Singapore

Sponsoring Group: The American Society of Hematology

Web Page URL: www.hematology.org/HOAAsia14Calendar

Objectives: At Highlights of ASH® in Asia you will hear hematology experts discuss the top clinical and translational research presented at the latest ASH annual meeting and how it can improve diagnosis and treatment of blood disorders and cancers

Who Should Attend: Hematologists, Hematologist-Oncologists, Hemapathologists, Oncologists, Allied Health Professionals

Continuing Education: No

Audience: HCP


News
ASH: Novel Drug Beneficial in Multiple Myeloma

Feb 27, 2015 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a high response rate and a low incidence of side effects, according to research presented at the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in New Orleans.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More